Loading stock data…
GRAIL, Inc. (GRAL)
$67.84-2.52 (-3.58%)
Market ClosedLast close Jul 24
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GRAIL, Inc. in the Healthcare sector is trading at $67.84 with a market capitalization of $2.6B. Wall Street consensus targets $70.12 (8 analysts), implying a +3.4% move over the next 12 months. The stock is currently 43% below its 52-week high of $118.84, remaining 8.7% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $40.78M↓ | $43.60M↑ | $36.19M↑ | $35.54M↑ | $31.84M |
| Gross Profit | -$14.31M↓ | -$11.14M↑ | -$13.73M↑ | -$17.77M↑ | -$19.93M |
| Operating Income | -$135.76M↓ | -$124.41M↑ | -$125.29M↑ | -$130.85M↑ | -$153.61M |
| Net Income | -$93.19M↑ | -$99.18M↓ | -$88.98M↑ | -$113.98M↓ | -$106.21M |
Peer Comparison
JNJUNHPFE
Fundamentals
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.62B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-15.81%
Volume
Today's trading volume
336,690
Recent News
Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong.
The fate of Grail's stock will ultimately be decided in the cost-benefit calculations of medical insurers.
Prediction: Grail Stock Will Skyrocket to $100 in 1 Year
The cancer test maker still has a bright future.
A Blood Test That Screens for 50+ Cancers Just Moved Closer to Real-World Use. Here's What It Means for Grail Investors.
Despite a significant setback, Grail's Galleri test still has a pathway to widespread adoption.
Honeywell Stock Is Likely to Reward Shareholders Following Quantinuum IPO, Split
HON will own a large stake in Quantinuum following the IPO.
A Look At GRAIL (GRAL) Valuation After A Sharp One Day Share Price Drop
GRAIL stock reaction and recent performance GRAIL (GRAL) shares recently moved after a single day decline of about 10%, drawing attention to how the stock’s sharp daily move compares with its gains over the past month and past 3 months. See our latest analysis for GRAIL. That 10.16% one day share price drop comes after a 19.13% 30 day share price return and a 22.06% 90 day share price return. Yet year to date the share price is still down 27.53%, even as the 1 year total shareholder return...